/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis ( MASH ) and obesity.
$1.73
+$0.14 (+8.81%)
EOD Sep 18, 2026
Negative free cash flow of -$16M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$14M
▲ +53.0% YoY
Op. Margin
—
ROIC
-167.20%
▲ +23.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$16M
▲ +36.5% YoY
Op. Cash Flow (TTM)
-$16M
▲ +36.5% YoY
Net Debt
-$12M
Net Cash Position
Cash & Equiv.
$13M
Continue Research
SourceComputed from the 10-Q filed 6 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.